Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

('Mediclinic', the 'Company'or the 'Group')

2 June 2017

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Awards under the Company's Short-Term Incentive Scheme

On 1 June 2017, awards over ordinary shares in Mediclinic (the 'Shares') were granted to the following Directors and other persons discharging managerial responsibilities ('PDMRs') under the rules of the Company's Short-Term Incentive ('STI') Scheme, which was approved by shareholders in December 2015:

Name

Director/ PDMR

Number of Shares awarded under the Short Term Incentive Scheme

Danie Meintjes

Director

27,187

Jurgens Myburgh

Director

10,815

Nil consideration per share was paid for the grant of the awards. The vesting of an award is subject to employment conditions; no further performance conditions apply.

The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's STI Scheme.

1.

Details of PDMR / person closely associated with them ('PCA')

a)

Name

Daniël Petrus Meintjes

2.

Reason for the notification

a)

Position / status

Chief Executive Officer of the Company

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted under the Company's Short Term Incentive Scheme

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil cost

27,187

d)

Aggregated information

Aggregated volume

Price

27,187

ZAR0.00

e)

Date of the transaction

1June 2017

f)

Place of the transaction

Johannesburg Stock Exchange

1.

Details of PDMR / person closely associated with them ('PCA')

a)

Name

Petrus Jurgens Myburgh

2.

Reason for the notification

a)

Position / status

Chief Financial Officer of the Company

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted under the Company's Short Term Incentive Scheme

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil cost

10,815

d)

Aggregated information

Aggregated volume

Price

10,815

ZAR0.00

e)

Date of the transaction

1 June 2017

f)

Place of the transaction

Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

+44 (0)207 954 9600

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website:www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor:RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor:Simonis Storm Securities (Pty) Ltd

Mediclinic International plc published this content on 02 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 June 2017 15:09:30 UTC.

Original documenthttp://ir.mediclinic.com/phoenix.zhtml?c=145797&p=irol-rnsArticle&ID=2278523

Public permalinkhttp://www.publicnow.com/view/1679D73902C71D583BE3CC9F75ECDF44C990A714